Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer

Our study aimed to evaluate the feasibility of adjuvant cyclophosphamide/vinorelbine/5-fluorourail (CVF) chemotherapy as an alternative to cyclophosphamide/methotrexate/5-fluorouracil (CMF) chemotherapy for treating early breast cancer. One hundred and forty-nine patients were randomly assigned to C...

Full description

Saved in:
Bibliographic Details
Published inJournal of breast cancer Vol. 14; no. 3; pp. 223 - 228
Main Authors Gwak, Geumhee, Park, Kyeongmee, Shin, Eunah, Han, Sehwan, Kim, Ji-Young, Kim, Hongyong, Kim, Young Duk, Kim, Hong Ju, Kim, Ki Whan, Bae, Byung Noe, Yang, Keun Ho, Cho, Hyunjin, Park, Sung-Jin
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Breast Cancer Society 01.09.2011
한국유방암학회
Subjects
Online AccessGet full text
ISSN1738-6756
2092-9900
2092-9900
DOI10.4048/jbc.2011.14.3.223

Cover

Abstract Our study aimed to evaluate the feasibility of adjuvant cyclophosphamide/vinorelbine/5-fluorourail (CVF) chemotherapy as an alternative to cyclophosphamide/methotrexate/5-fluorouracil (CMF) chemotherapy for treating early breast cancer. One hundred and forty-nine patients were randomly assigned to CMF or CVF adjuvant chemotherapy for treating their early stage breast cancer between September 2000 and December 2007. The disease-free survival (DFS), the overall survival (OS), and the toxicity profiles of both groups were compared. Sixty-seven patients underwent CMF chemotherapy whereas 82 patients underwent CVF chemotherapy. The DFS and OS were 88 months (95% confidence interval [CI], 76-101 months) and 94 months (95% CI, 83-104 months), respectively for the CMF group, and 97 months (95% CI, 93-101 months), and 101 months (95% CI, 98-104 months), respectively for the CVF group. However, those survival gains of the CVF group were not statistically significant (p-value=0.069 for the DFS and 0.99 for the OS). The CVF group showed a favorable toxicity profile in terms of the grade 3/4 hematologic toxicities as compared to that of the CMF group. Clinical outcome of CVF chemotherapy was comparable to CMF with a favorable toxicity profiles. However, it is difficult to conclude the feasibility of CVF regimen because of small number of studied patients.
AbstractList Our study aimed to evaluate the feasibility of adjuvant cyclophosphamide/vinorelbine/5-fluorourail (CVF) chemotherapy as an alternative to cyclophosphamide/methotrexate/5-fluorouracil (CMF) chemotherapy for treating early breast cancer. One hundred and forty-nine patients were randomly assigned to CMF or CVF adjuvant chemotherapy for treating their early stage breast cancer between September 2000 and December 2007. The disease-free survival (DFS), the overall survival (OS), and the toxicity profiles of both groups were compared. Sixty-seven patients underwent CMF chemotherapy whereas 82 patients underwent CVF chemotherapy. The DFS and OS were 88 months (95% confidence interval [CI], 76-101 months) and 94 months (95% CI, 83-104 months), respectively for the CMF group, and 97 months (95% CI, 93-101 months), and 101 months (95% CI, 98-104 months), respectively for the CVF group. However, those survival gains of the CVF group were not statistically significant (p-value=0.069 for the DFS and 0.99 for the OS). The CVF group showed a favorable toxicity profile in terms of the grade 3/4 hematologic toxicities as compared to that of the CMF group. Clinical outcome of CVF chemotherapy was comparable to CMF with a favorable toxicity profiles. However, it is difficult to conclude the feasibility of CVF regimen because of small number of studied patients.
Our study aimed to evaluate the feasibility of adjuvant cyclophosphamide/vinorelbine/5-fluorourail (CVF) chemotherapy as an alternative to cyclophosphamide/methotrexate/5-fluorouracil (CMF) chemotherapy for treating early breast cancer.PURPOSEOur study aimed to evaluate the feasibility of adjuvant cyclophosphamide/vinorelbine/5-fluorourail (CVF) chemotherapy as an alternative to cyclophosphamide/methotrexate/5-fluorouracil (CMF) chemotherapy for treating early breast cancer.One hundred and forty-nine patients were randomly assigned to CMF or CVF adjuvant chemotherapy for treating their early stage breast cancer between September 2000 and December 2007. The disease-free survival (DFS), the overall survival (OS), and the toxicity profiles of both groups were compared.METHODSOne hundred and forty-nine patients were randomly assigned to CMF or CVF adjuvant chemotherapy for treating their early stage breast cancer between September 2000 and December 2007. The disease-free survival (DFS), the overall survival (OS), and the toxicity profiles of both groups were compared.Sixty-seven patients underwent CMF chemotherapy whereas 82 patients underwent CVF chemotherapy. The DFS and OS were 88 months (95% confidence interval [CI], 76-101 months) and 94 months (95% CI, 83-104 months), respectively for the CMF group, and 97 months (95% CI, 93-101 months), and 101 months (95% CI, 98-104 months), respectively for the CVF group. However, those survival gains of the CVF group were not statistically significant (p-value=0.069 for the DFS and 0.99 for the OS). The CVF group showed a favorable toxicity profile in terms of the grade 3/4 hematologic toxicities as compared to that of the CMF group.RESULTSSixty-seven patients underwent CMF chemotherapy whereas 82 patients underwent CVF chemotherapy. The DFS and OS were 88 months (95% confidence interval [CI], 76-101 months) and 94 months (95% CI, 83-104 months), respectively for the CMF group, and 97 months (95% CI, 93-101 months), and 101 months (95% CI, 98-104 months), respectively for the CVF group. However, those survival gains of the CVF group were not statistically significant (p-value=0.069 for the DFS and 0.99 for the OS). The CVF group showed a favorable toxicity profile in terms of the grade 3/4 hematologic toxicities as compared to that of the CMF group.Clinical outcome of CVF chemotherapy was comparable to CMF with a favorable toxicity profiles. However, it is difficult to conclude the feasibility of CVF regimen because of small number of studied patients.CONCLUSIONClinical outcome of CVF chemotherapy was comparable to CMF with a favorable toxicity profiles. However, it is difficult to conclude the feasibility of CVF regimen because of small number of studied patients.
Purpose: Our study aimed to evaluate the feasibility of adjuvant cyclophosphamide/vinorelbine/5-fluorourail (CVF) chemotherapy as an alternative to cyclophosphamide/methotrexate/5-fluorouracil (CMF) chemotherapy for treating early breast cancer. Methods: One hundred and forty-nine patients were randomly assigned to CMF or CVF adjuvant chemotherapy for treating their early stage breast cancer between September 2000 and December 2007. The disease-free survival (DFS), the overall survival (OS), and the toxicity profiles of both groups were compared. Results: Sixty-seven patients underwent CMF chemotherapy whereas 82 patients underwent CVF chemotherapy. The DFS and OS were 88 months (95% confidence interval [CI], 76-101 months) and 94 months (95% CI, 83-104 months), respectively for the CMF group, and 97 months (95% CI, 93-101 months), and 101 months (95% CI, 98-104 months), respectively for the CVF group. However, those survival gains of the CVF group were not statistically significant (p-value=0.069 for the DFS and 0.99 for the OS). The CVF group showed a favorable toxicity profile in terms of the grade 3/4 hematologic toxicities as compared to that of the CMF group. Conclusion: Clinical outcome of CVF chemotherapy was comparable to CMF with a favorable toxicity profiles. However, it is difficult to conclude the feasibility of CVF regimen because of small number of studied patients. KCI Citation Count: 0
Author Cho, Hyunjin
Gwak, Geumhee
Kim, Young Duk
Bae, Byung Noe
Kim, Hong Ju
Shin, Eunah
Kim, Ki Whan
Park, Kyeongmee
Yang, Keun Ho
Kim, Ji-Young
Han, Sehwan
Kim, Hongyong
Park, Sung-Jin
AuthorAffiliation 4 Department of Surgery, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea
3 Department of Surgery, Ilsan Hospital, Dongguk University College of Medicine, Goyang, Korea
2 Department of Radiology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea
Department of Surgery, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea
1 Department of Pathology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea
AuthorAffiliation_xml – name: 4 Department of Surgery, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea
– name: Department of Surgery, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea
– name: 1 Department of Pathology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea
– name: 3 Department of Surgery, Ilsan Hospital, Dongguk University College of Medicine, Goyang, Korea
– name: 2 Department of Radiology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea
Author_xml – sequence: 1
  givenname: Geumhee
  surname: Gwak
  fullname: Gwak, Geumhee
  organization: Department of Surgery, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea
– sequence: 2
  givenname: Kyeongmee
  surname: Park
  fullname: Park, Kyeongmee
  organization: Department of Pathology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea
– sequence: 3
  givenname: Eunah
  surname: Shin
  fullname: Shin, Eunah
  organization: Department of Pathology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea
– sequence: 4
  givenname: Sehwan
  surname: Han
  fullname: Han, Sehwan
  organization: Department of Surgery, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea
– sequence: 5
  givenname: Ji-Young
  surname: Kim
  fullname: Kim, Ji-Young
  organization: Department of Radiology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea
– sequence: 6
  givenname: Hongyong
  surname: Kim
  fullname: Kim, Hongyong
  organization: Department of Surgery, Ilsan Hospital, Dongguk University College of Medicine, Goyang, Korea
– sequence: 7
  givenname: Young Duk
  surname: Kim
  fullname: Kim, Young Duk
  organization: Department of Surgery, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea
– sequence: 8
  givenname: Hong Ju
  surname: Kim
  fullname: Kim, Hong Ju
  organization: Department of Surgery, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea
– sequence: 9
  givenname: Ki Whan
  surname: Kim
  fullname: Kim, Ki Whan
  organization: Department of Surgery, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea
– sequence: 10
  givenname: Byung Noe
  surname: Bae
  fullname: Bae, Byung Noe
  organization: Department of Surgery, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea
– sequence: 11
  givenname: Keun Ho
  surname: Yang
  fullname: Yang, Keun Ho
  organization: Department of Surgery, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea
– sequence: 12
  givenname: Hyunjin
  surname: Cho
  fullname: Cho, Hyunjin
  organization: Department of Surgery, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea
– sequence: 13
  givenname: Sung-Jin
  surname: Park
  fullname: Park, Sung-Jin
  organization: Department of Surgery, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22031805$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001591211$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNqNkctu1DAUhi1URKeFB2CDsqOoSji-5OIN0hB1oFIrJDTq1nISh3jq2KmdFPI8vCgZptwEC1Zncf7LOfpO0JF1ViH0HEPCgBWvd1WdEMA4wSyhCSH0EVoR4CTmHOAIrXBOizjL0-wYnYSwA8gYzfMn6JgQoLiAdIW-lq4fpNfB2ci1UXmzic7KuTZu6FwYOtnrRp3faOu8MpW26jyNN2Zy3k1e1tq8iqRtovL6X65rNXZu9OqLHP-2rZvddC_tGJWd6t3YKS-HOdI2upDezNFbr2RYltLWyj9Fj1tpgnr2ME_RdnOxLd_HVx_eXZbrq7imBR1jDLyQeQW8LjhRVZO3-29Z1vIsA8Zz0lBOZApNBm1D01ZizjgtSJtnRZUTeorODrHWt-K21sJJ_X1-cuLWi_XH7aVgPCsIXqTkIJ3sIOfP0hgxeN1LPwsMYs9GLGzEno3ATFCxsFlMbw6mYap61dTKjl7-Mu7b_txY3S3d94ISgBTzJeDlQ4B3d5MKo-h1qJUx0io3BcEBAwBLYVG--L3qZ8cP7osAHwS1dyF41f7H_d8ALs7CDg
Cites_doi 10.1200/JCO.1995.13.11.2722
10.1093/annonc/mdi276
10.1007/BF01805984
10.1080/02841860310004373
10.1200/JCO.2004.11.503
10.1016/S0140-6736(05)66544-0
10.1200/JCO.1993.11.7.1245
10.4048/jkbcs.2004.7.4.289
10.1200/JCO.1994.12.10.2094
10.1200/JCO.1995.13.12.2886
10.1200/JCO.1990.8.9.1483
10.1200/JCO.2005.09.423
10.1159/000216938
10.1159/000163056
10.1093/jnci/djn085
10.1136/bmj.38314.622095.8F
10.1007/s10549-004-1001-0
10.1038/sj.bjc.6603773
10.7326/0003-4819-89-1-107
10.2174/187152008785914798
10.1093/jnci/djp092
ContentType Journal Article
Copyright 2011 Korean Breast Cancer Society 2011
Copyright_xml – notice: 2011 Korean Breast Cancer Society 2011
DBID AAYXX
CITATION
NPM
7X8
5PM
ADTOC
UNPAY
ACYCR
DOI 10.4048/jbc.2011.14.3.223
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
Korean Citation Index
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2092-9900
EndPage 228
ExternalDocumentID oai_kci_go_kr_ARTI_496821
10.4048/jbc.2011.14.3.223
PMC3200519
22031805
10_4048_jbc_2011_14_3_223
Genre Journal Article
GroupedDBID ---
5-W
5GY
8JR
8XY
9ZL
AAYXX
ADBBV
ADRAZ
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
DU5
EF.
GROUPED_DOAJ
HYE
KQ8
M48
O5R
O5S
PGMZT
RPM
NPM
7X8
5PM
ADTOC
UNPAY
ACYCR
ID FETCH-LOGICAL-c383t-1098a7b09c892ebd7f437746f96604972d392a50d60fd35fa1949382f768b723
IEDL.DBID M48
ISSN 1738-6756
2092-9900
IngestDate Tue Nov 21 21:30:10 EST 2023
Tue Aug 19 19:21:49 EDT 2025
Thu Aug 21 18:08:20 EDT 2025
Fri Jul 11 08:46:31 EDT 2025
Mon Jul 21 05:55:37 EDT 2025
Tue Jul 01 01:56:40 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Adjuvant chemotherapy
Cyclophosphamide
Breast neoplasms
Methotrexate
Vinorelbine
Fluorouracil
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
cc-by-nc
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c383t-1098a7b09c892ebd7f437746f96604972d392a50d60fd35fa1949382f768b723
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
G704-SER000010237.2011.14.3.007
OpenAccessLink https://proxy.k.utb.cz/login?url=http://ejbc.kr/Synapse/Data/PDFData/0096JBC/jbc-14-223.pdf
PMID 22031805
PQID 901000450
PQPubID 23479
PageCount 6
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_496821
unpaywall_primary_10_4048_jbc_2011_14_3_223
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3200519
proquest_miscellaneous_901000450
pubmed_primary_22031805
crossref_primary_10_4048_jbc_2011_14_3_223
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2011-09-01
PublicationDateYYYYMMDD 2011-09-01
PublicationDate_xml – month: 09
  year: 2011
  text: 2011-09-01
  day: 01
PublicationDecade 2010
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Journal of breast cancer
PublicationTitleAlternate J Breast Cancer
PublicationYear 2011
Publisher Korean Breast Cancer Society
한국유방암학회
Publisher_xml – name: Korean Breast Cancer Society
– name: 한국유방암학회
References Tancini (10.4048/jbc.2011.14.3.223_ref6) 1979; 2
Slamon (10.4048/jbc.2011.14.3.223_ref21) 2009; 101
Chua (10.4048/jbc.2011.14.3.223_ref13) 2005; 16
von Minckwitz (10.4048/jbc.2011.14.3.223_ref25) 2008; 100
Cosse (10.4048/jbc.2011.14.3.223_ref2) 2008; 8
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (10.4048/jbc.2011.14.3.223_ref23) 2005; 365
Weber (10.4048/jbc.2011.14.3.223_ref14) 1995; 13
Julka (10.4048/jbc.2011.14.3.223_ref4) 1999; 47
Bonadonna (10.4048/jbc.2011.14.3.223_ref5) 1978; 48
Kerbrat (10.4048/jbc.2011.14.3.223_ref17) 2007; 96
Gasparini (10.4048/jbc.2011.14.3.223_ref11) 1994; 12
Elomaa (10.4048/jbc.2011.14.3.223_ref15) 2003; 42
Heys (10.4048/jbc.2011.14.3.223_ref3) 2005; 90
Vici (10.4048/jbc.2011.14.3.223_ref16) 2008; 75
Fisher (10.4048/jbc.2011.14.3.223_ref19) 1990; 8
Ardavanis (10.4048/jbc.2011.14.3.223_ref24) 1998; 12
Valero (10.4048/jbc.2011.14.3.223_ref20) 1995; 13
Bonadonna (10.4048/jbc.2011.14.3.223_ref7) 1985; 5
Ejlertsen (10.4048/jbc.2011.14.3.223_ref12) 2004; 22
Cho (10.4048/jbc.2011.14.3.223_ref18) 2004; 7
Levine (10.4048/jbc.2011.14.3.223_ref22) 2005; 23
Krikorian (10.4048/jbc.2011.14.3.223_ref9) 1991; 14
Fumoleau (10.4048/jbc.2011.14.3.223_ref10) 1993; 11
Bonadonna (10.4048/jbc.2011.14.3.223_ref8) 2005; 330
Shackney (10.4048/jbc.2011.14.3.223_ref1) 1978; 89
References_xml – volume: 13
  start-page: 2722
  year: 1995
  ident: 10.4048/jbc.2011.14.3.223_ref14
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1995.13.11.2722
– volume: 16
  start-page: 1435
  year: 2005
  ident: 10.4048/jbc.2011.14.3.223_ref13
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdi276
– volume: 5
  start-page: 95
  year: 1985
  ident: 10.4048/jbc.2011.14.3.223_ref7
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/BF01805984
– volume: 2
  start-page: 285
  year: 1979
  ident: 10.4048/jbc.2011.14.3.223_ref6
  publication-title: Cancer Clin Trials
– volume: 42
  start-page: 309
  year: 2003
  ident: 10.4048/jbc.2011.14.3.223_ref15
  publication-title: Acta Oncol
  doi: 10.1080/02841860310004373
– volume: 22
  start-page: 2313
  year: 2004
  ident: 10.4048/jbc.2011.14.3.223_ref12
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2004.11.503
– volume: 365
  start-page: 1687
  year: 2005
  ident: 10.4048/jbc.2011.14.3.223_ref23
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)66544-0
– volume: 11
  start-page: 1245
  year: 1993
  ident: 10.4048/jbc.2011.14.3.223_ref10
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1993.11.7.1245
– volume: 7
  start-page: 289
  year: 2004
  ident: 10.4048/jbc.2011.14.3.223_ref18
  publication-title: J Korean Breast Cancer Soc
  doi: 10.4048/jkbcs.2004.7.4.289
– volume: 12
  start-page: 2094
  year: 1994
  ident: 10.4048/jbc.2011.14.3.223_ref11
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1994.12.10.2094
– volume: 13
  start-page: 2886
  year: 1995
  ident: 10.4048/jbc.2011.14.3.223_ref20
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1995.13.12.2886
– volume: 8
  start-page: 1483
  year: 1990
  ident: 10.4048/jbc.2011.14.3.223_ref19
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1990.8.9.1483
– volume: 23
  start-page: 5166
  year: 2005
  ident: 10.4048/jbc.2011.14.3.223_ref22
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.09.423
– volume: 14
  start-page: 7
  year: 1991
  ident: 10.4048/jbc.2011.14.3.223_ref9
  publication-title: Onkologie
  doi: 10.1159/000216938
– volume: 75
  start-page: 175
  year: 2008
  ident: 10.4048/jbc.2011.14.3.223_ref16
  publication-title: Oncology
  doi: 10.1159/000163056
– volume: 100
  start-page: 542
  year: 2008
  ident: 10.4048/jbc.2011.14.3.223_ref25
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djn085
– volume: 330
  start-page: 217
  year: 2005
  ident: 10.4048/jbc.2011.14.3.223_ref8
  publication-title: BMJ
  doi: 10.1136/bmj.38314.622095.8F
– volume: 90
  start-page: 169
  year: 2005
  ident: 10.4048/jbc.2011.14.3.223_ref3
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-004-1001-0
– volume: 96
  start-page: 1633
  year: 2007
  ident: 10.4048/jbc.2011.14.3.223_ref17
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6603773
– volume: 89
  start-page: 107
  year: 1978
  ident: 10.4048/jbc.2011.14.3.223_ref1
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-89-1-107
– volume: 8
  start-page: 790
  year: 2008
  ident: 10.4048/jbc.2011.14.3.223_ref2
  publication-title: Anticancer Agents Med Chem
  doi: 10.2174/187152008785914798
– volume: 47
  start-page: 499
  year: 1999
  ident: 10.4048/jbc.2011.14.3.223_ref4
  publication-title: J Assoc Physicians India
– volume: 101
  start-page: 615
  year: 2009
  ident: 10.4048/jbc.2011.14.3.223_ref21
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djp092
– volume: 12
  start-page: 559
  year: 1998
  ident: 10.4048/jbc.2011.14.3.223_ref24
  publication-title: In Vivo
– volume: 48
  start-page: 659
  year: 1978
  ident: 10.4048/jbc.2011.14.3.223_ref5
  publication-title: Arch Geschwulstforsch
SSID ssj0064377
Score 1.8289342
Snippet Our study aimed to evaluate the feasibility of adjuvant cyclophosphamide/vinorelbine/5-fluorourail (CVF) chemotherapy as an alternative to...
Purpose: Our study aimed to evaluate the feasibility of adjuvant cyclophosphamide/vinorelbine/5-fluorourail (CVF) chemotherapy as an alternative to...
SourceID nrf
unpaywall
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 223
SubjectTerms Original
일반외과학
SummonAdditionalLinks – databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLVYJwEvfA_Cl4zEAzAlTW0nTR67jGpM6jSJbRriwbJjh2YNSZQmgvJ3-KNcp2mh6iQEUqQ8xI5l59j33Pj6XIReU6YCzxfUprF0baZCactQwmIoAun7CVxt_pTJiX90zo4vvcvfUZX6SsbOrOp_XOSinOv-oahF__Rw3N4N3T4-iPpQxh4wGwybU6pkB-36ZnOph3bPT05Hn9oTkDCLgQm3meXckNiw5HZbmszo1JpGWvHOAXOoQwjdMEo7eZVcxze3wyZvNXkpFt9Elv1hk8Z30efVyZ5lKMrMaWrpxD-2hR7_o7v30J2OquLRElv30Q2dP0A3J91m_EP0M1rnMMRFgqOLMX4TLeKsKKfFvJyKr6nS-xdpXlQ6k4bMevY4a4oK3iviNHuLRa5wNLmu1sTkta4r_R2Y8Fa1kbpqgP_X2IgddAfIFjjNcSvWjA9MmD08NHCuHqGz8fuz6Mjucj7YMfjKNViFMBBD6YZxEBIt1TBhFBiqnxgVURYOiQJCJzxX-W6iqJeIQchCGpAE3CY5JHQP9fIi108QVm6QMOUTGQOFITGVQvieFGAZNDGqeRZ6t_rmvFwqe3DwiAxAOAw5NwABx4hTDiNvoVeACj6LU270uM39S8FnFQev4wNnoR-QgYXwCjMc5qjZeBG5Lpo5NyEwhju7Fnq8hNC6RULMqup6FhpugGtdwDS3-SRPp60MOCUt_7bQ_hqGf-_I038q_QzdXv5DNzF1z1Gvrhr9AkhYLV92s-0Xl78s8Q
  priority: 102
  providerName: Unpaywall
Title Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/22031805
https://www.proquest.com/docview/901000450
https://pubmed.ncbi.nlm.nih.gov/PMC3200519
http://ejbc.kr/Synapse/Data/PDFData/0096JBC/jbc-14-223.pdf
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001591211
UnpaywallVersion publishedVersion
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Journal of Breast Cancer, 2011, 14(3), 55, pp.223-228
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2092-9900
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0064377
  issn: 2092-9900
  databaseCode: KQ8
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2092-9900
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0064377
  issn: 2092-9900
  databaseCode: DOA
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2092-9900
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0064377
  issn: 2092-9900
  databaseCode: DIK
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVERR
  databaseName: KoreaMed Open Access
  customDbUrl:
  eissn: 2092-9900
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0064377
  issn: 2092-9900
  databaseCode: 5-W
  dateStart: 20050101
  isFulltext: true
  titleUrlDefault: https://koreamed.org/journals
  providerName: Korean Association of Medical Journal Editors
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2092-9900
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0064377
  issn: 2092-9900
  databaseCode: RPM
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 2092-9900
  dateEnd: 20250630
  omitProxy: true
  ssIdentifier: ssj0064377
  issn: 2092-9900
  databaseCode: M48
  dateStart: 20110301
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1ba9swFBa9wLaXsWvnXYIGY2wrDo4s355GZha6gcsemtI9CcmyF7ee7ToOa37P_ujOsR2z0EDB4AdbvuiTjr6jI32HkHc2177jStu0Y2WZXAfKVIECYyh95bopHG3-lOjUPZnz7xfOxR7ZRM_7ClzudO0wn9S8zsc31-vP0OGBv445ys5eqrjT4pzwsT2G8e59dW1iXimMv_ZJNvbJIYxVDNt9xIc4A0atcEM1swJmgl3u4567n7o1cu0XdbqLlN5eW3l_VVRy_Ufm-X8D1-wRedgzTjrtmshjspcUT8i9qI-pPyV_wyEVIS1TGp7P6IdwHedltSiX1UL-znRyfJ4VZZ3kCjmpY87yVVnDc2Wc5R-pLDQNo12lIkxP3dTJDRDaW8Wm-nIFNL6hqFnQ7wNb06ygreYy_YKr5eEitsr6GTmbfT0LT8w-dYMZg8vbgHEPfOkpK4j9gCVKeynWNHdTFAPlgcc08DLpWNq1Um07qZwEPLB9loL3ozxmPycHRVkkLwjVlp9y7TIVAxNhsa2kdB0lwcAnDMXvDPJpg4qoOoEOAY4NQigAQoEQgn8jbAEQGuQt4Cau4kygrDaef5XiqhbgPHwTPHB9NjEI3aAqoKth_EQWSblaClzJghTYMshRB_LwRsbQOFqOQbwt-Icb8HXbV4ps0ap526yl0QY5HhrK3T_y8u6PfEUedPPfuB7uNTlo6lXyBghUo0btxMOo7Qmjdn5rRA7npz-mP_8BIt0dWQ
linkProvider Scholars Portal
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLVYJwEvfA_Cl4zEAzAlTW0nTR67jGpM6jSJbRriwbJjh2YNSZQmgvJ3-KNcp2mh6iQEUqQ8xI5l59j33Pj6XIReU6YCzxfUprF0baZCactQwmIoAun7CVxt_pTJiX90zo4vvcvfUZX6SsbOrOp_XOSinOv-oahF__Rw3N4N3T4-iPpQxh4wGwybU6pkB-36ZnOph3bPT05Hn9oTkDCLgQm3meXckNiw5HZbmszo1JpGWvHOAXOoQwjdMEo7eZVcxze3wyZvNXkpFt9Elv1hk8Z30efVyZ5lKMrMaWrpxD-2hR7_o7v30J2OquLRElv30Q2dP0A3J91m_EP0M1rnMMRFgqOLMX4TLeKsKKfFvJyKr6nS-xdpXlQ6k4bMevY4a4oK3iviNHuLRa5wNLmu1sTkta4r_R2Y8Fa1kbpqgP_X2IgddAfIFjjNcSvWjA9MmD08NHCuHqGz8fuz6Mjucj7YMfjKNViFMBBD6YZxEBIt1TBhFBiqnxgVURYOiQJCJzxX-W6iqJeIQchCGpAE3CY5JHQP9fIi108QVm6QMOUTGQOFITGVQvieFGAZNDGqeRZ6t_rmvFwqe3DwiAxAOAw5NwABx4hTDiNvoVeACj6LU270uM39S8FnFQev4wNnoR-QgYXwCjMc5qjZeBG5Lpo5NyEwhju7Fnq8hNC6RULMqup6FhpugGtdwDS3-SRPp60MOCUt_7bQ_hqGf-_I038q_QzdXv5DNzF1z1Gvrhr9AkhYLV92s-0Xl78s8Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+CVF+%28Cyclophosphamide%2BVinorelbine%2B5-Fluorouracil%29+and+CMF+%28Cyclophosphamide%2BMethotrexate%2B5-Fluorouracil%29+Adjuvant+Chemotherapy+in+Early+Breast+Cancer&rft.jtitle=Journal+of+breast+cancer&rft.au=Gwak%2C+Geumhee&rft.au=Park%2C+Kyeongmee&rft.au=Shin%2C+Eunah&rft.au=Han%2C+Sehwan&rft.date=2011-09-01&rft.issn=2092-9900&rft.eissn=2092-9900&rft.volume=14&rft.issue=3&rft.spage=223&rft_id=info:doi/10.4048%2Fjbc.2011.14.3.223&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1738-6756&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1738-6756&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1738-6756&client=summon